Newsroom | 19000 results

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics launches Dyno Psi-Phi, an agentic AI suite for protein binder design, at NVIDIA GTC 2026...

BERKELEY, Calif.--(BUSINESS WIRE)--The AI revolution in biology is built on a foundation of openness —researchers sharing data, code, and ideas freely so that others can build on them....

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California taking place April 17 - 22, 2026. Key data that will be presented include: An oral present...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (FTD). The study has been published in the pee...

PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, inherited, neurometabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has selected ECUR-506, the company’s investigational in vivo targeted gene insertion therapy for neonatal-onset ornithine transcarbamylase (OTC) deficiency, to participate in the Chemistry, Manufacturing, and Cont...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Mirecule expands strategic collaboration with Sanofi on advancement of best-in-class ARC treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)...

SAN DIEGO--(BUSINESS WIRE)--Researchers at Inocras, a bioinformatics-led precision health company harnessing the power of whole-genome sequencing (WGS) data and proprietary analytics, and the Broad Institute jointly announced the upcoming release of key insights from whole-genome analysis of over 8,000 public cancer whole genomes. This analysis aims to deliver one of the largest genome-wide landscapes of somatic mutations across human pan-cancers. “NCI’s public The Cancer Genome Atlas (TCGA) ef...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News : Sensorion (FR0012596468 – ALSEN), Société pionnière de biotechnologie au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer, traiter et prévenir les troubles de la perte auditive, publie aujourd'hui ses résultats annuels 2025, présente une mise à jour de sa feuille de route et annonce la mise à disposition du rapport annuel. « L'année écoulée a été une période de progrès exceptionnels, tant au niveau de...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2025 results, provided a corporate update, and announced the availability of the annual report. “This past year has been an exceptional period of progress across our pipeline and on the corporate development front.” commented A...

英国オックスフォード&東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- ナノポアを基盤とした新世代の分子センシング技術を提供するオックスフォード・ナノポアテクノロジーズと、日本有数の遺伝子検査企業であるA.D.A.M.イノベーションズ（日本社名：ジェネシスヘルスケア株式会社）は、日本において、包括的なナノポアシーケンシングに基づく先進的なゲノムシーケンシングおよびゲノム医療応用の開発と展開に向けた国際的な協業を発表しました。 本協業の初期段階では、オックスフォード・ナノポアの情報量の豊富なリアルタイムシーケンシング技術をA.D.A.M.イノベーションズの先進的な遺伝子検査ポートフォリオ 全体に展開できる可能性があり、複数の疾患領域において迅速かつ高精度なゲノム検査を実現します。本協業の目的は、日本固有のバリデーション基準に基づく新たな臨床ワークフローを導入し、さまざまな疾患や病態に対応するため、あらゆる長さのDNA断片の拡張可能なシーケンシングを支援することです。完全なゲノム情報を捉えるシーケンシングにより、既存技術で達成可能な範囲を超えて検査精度を向上させます。...